Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) stated on Friday that it has launched the US Food and Drug Administration (USFDA) approved Deferasirox Tablets for oral suspension in the US market.
According to the company, Deferasirox Tablets for oral suspension are available in 125 mg, 250 mg and 500 mg dosage strengths in bottle count sizes of 30.
Dr Reddy's Deferasirox Tablets for oral suspension are a therapeutically equivalent generic version of Exjade (deferasirox) tablets for oral suspension.
For the most recent 12 months ending in September 2019, the Exjade brand had US sales of about USD113m MAT, according to IQVIA Health. Exjade (deferasirox) tablets for oral suspension are indicated for the treatment of chronically elevated levels of iron in the blood caused by repeated blood transfusions (transfusional hemosiderosis) in patients two years of age and older.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval